NICE NG196 2021: atrial fibrillation diagnosis and management

Who it applies to

Adults with or suspected of having atrial fibrillation (including atrial flutter) in primary and secondary care settings.

Key recommendations

• Use manual pulse palpation to detect an irregular pulse. An ECG (either a 12-lead ECG or an ECG rhythm strip) can be used to confirm the diagnosis of AF, with a 12-lead ECG indicated if there are concerns about other cardiac abnormalities.
• Use the CHA2DS2-VASc score to assess stroke risk in people with any type of AF (paroxysmal, persistent, or permanent), and the ORBIT score as the primary tool to assess bleeding risk, using HAS-BLED only if ORBIT is not available.
• Offer anticoagulation to people with a CHA2DS2-VASc score of 2 or more, and consider it for men with a score of 1, taking bleeding risk into account.
• Do not withhold anticoagulation solely because of age or falls risk alone.
• Offer a direct oral anticoagulant (DOAC) in preference to a vitamin K antagonist for most people with AF who need anticoagulation, in line with NICE technology appraisals.
• Do not offer aspirin monotherapy solely for stroke prevention in AF.
• Offer rate control as the first-line strategy for most people with AF, using a beta-blocker or a rate-limiting calcium-channel blocker.
• Consider rhythm control (cardioversion, antiarrhythmic drugs, or ablation) when AF has a reversible cause, when rate control fails, or when rhythm control is more appropriate clinically or is the person's preference.
• For new-onset AF presenting acutely, consider rate or rhythm control depending on haemodynamic stability and duration of symptoms, following local protocols for emergency cardioversion.
• Consider left atrial catheter ablation for people with symptomatic paroxysmal or persistent AF when drug treatment has not controlled symptoms.
• Reassess stroke and bleeding risk periodically, as these can change over time, rather than performing a one-off assessment.

What is new in this edition

• Introduced the ORBIT bleeding risk tool as the primary tool for assessing bleeding risk, with HAS-BLED to be used only if ORBIT is unavailable.
• Strengthened the recommendation for DOACs over vitamin K antagonists as first-line anticoagulants for most patients.
• Clarified that anticoagulation decisions should not be based on AF pattern (paroxysmal versus persistent versus permanent) alone.
• Clarified that an ECG rhythm strip can be used to confirm the diagnosis of AF, not only a 12-lead ECG.

Practice points for students

• Remember the CHA2DS2-VASc threshold: offer anticoagulation at a score of 2 or more (regardless of sex), and consider it for men with a score of 1.
• Aspirin alone is not an acceptable stroke prevention strategy in AF.
• Irregular pulse on palpation should prompt an ECG, which can be a 12-lead ECG or a rhythm strip; use a 12-lead ECG if other cardiac abnormalities are suspected.
• Rate control is the default strategy; rhythm control is reserved for specific indications or patient preference.
• Bleeding risk scores identify modifiable risk factors to address, not an automatic reason to withhold anticoagulation.

Condition

Other guidelines on this topic

• 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice GuidelinesAHA/ACC2024Summary
• 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)ESC2024Summary
• Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel ReportCHEST2018Summary

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by NICE. It is not medical advice: always read the original guideline before applying it to patients.